Topic: New Therapies for Metastatic Non-Small Cell Lung Cancer

Lung cancer is the second most common cancer worldwide and the leading cause of cancer deaths. Unfortunately, nearly 80% of patients with lung cancer are diagnosed with regional or metastatic disease, which has a poor prognosis. The current treatment options for lung cancer include surgery, chemotherapy, and radiotherapy. However, in recent years there have been advancements in immunotherapy and targeted therapies that are changing the way we treat this disease. Despite these advancements, there are still challenges to overcome such as drug resistance and toxicity. In this Special Issue, our goal is to publish high-quality research that provides an update on new therapies for metastatic non-small cell lung cancer (NSCLC) and discuss future prospects.

Potential topics of interest include but are not limited to:

1. The role of neoadjuvant and adjuvant therapy in surgically managing NSCLC;

2. Improvements in multimodality therapy for lung cancer;

3. Safety profile and adverse events associated with radiotherapy in lung cancer;

4. Identification of novel therapeutic targets for lung cancer treatment;

5. Novel drug resistance mechanisms in molecular targeted therapies for lung cancer;

6. Biomarkers for predicting response and prognosis to targeted/immuno therapies;

7. Impact of the tumor microenvironment on immunotherapy effectiveness in lung cancer;

8. Strategies to overcome immunotherapy resistance in NSCLC;

9. Ongoing or recently completed clinical trials investigating emerging drugs for NSCLC;

10. Comprehensive management of quality of life and care for NSCLC patients, including pain management and psychological support;

11. The evolving role of artificial intelligence and machine learning in personalized lung cancer treatment;

12. Combination therapies: Assessing the synergistic effects of immunotherapy and targeted therapy in NSCLC;

13. Patient perspectives: Understanding the lived experiences and preferences of NSCLC patients regarding treatment options;

14. Immunotherapy in elderly patients with NSCLC: Efficacy, safety, and considerations for tailored treatment;

15. Exploring the impact of lifestyle and environmental factors on NSCLC incidence and treatment outcomes;

16. Novel delivery systems for targeted therapies in lung cancer: nanoparticles, nanocarriers, and beyond;

17. Immunotherapy-induced autoimmune reactions in NSCLC: Recognition, management, and implications for treatment continuation;

18. The role of patient advocacy and support groups in enhancing NSCLC research, treatment, and patient well-being.

31 May 2024